Completed PHASE3 INTERVENTIONAL NCT00004650

Phase III Randomized Study of the Effect of Postmenopausal Estrogen Replacement Therapy on Alveolar Bone Loss

Sponsor: National Institute of Dental and Craniofacial Research (NIDCR)

Interventions Medroxyprogesterone conjugated estrogens

Updated 5 times since 2017 Last updated: Jun 23, 2005 Started: Aug 31, 1993

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Osteoporosis and is currently completed. National Institute of Dental and Craniofacial Research (NIDCR) leads this study, which shows 5 recorded versions since 1993 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Aug 1993

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Dental and Craniofacial Research (NIDCR)
Washington University School of Medicine

Data source: Office of Rare Diseases (ORD)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.